Teclistamab (Tecvayli, Johnson & Johnson Innovative Medicine) is indicated 'as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy'.
The dosage schedule is available in the summary of product characteristics for teclistamab.
The list price for teclistamab is £775.14 per 10‑mg vial and £3,952.78 per 90‑mg vial (excluding VAT, BNF online accessed June 2024).
The company has a commercial arrangement. This makes teclistamab available to the NHS with a discount. The size of the discount is commercial in confidence.